Embrace and Quality of Life (EMBQL)

Quality of Life in Epilepsy Patients Wearing a Biosensor for Seizure Detection Through Electrodermal Activity and Accelerometry - a Pilot Study

A prospective, open, randomized, pilot clinical trial which aims the assessment of quality of life (QOL) in epilepsy outpatients equipped with a wrist-worn biosensor that provides measures of electrodermal activity and accelerometry. These measures are used to automatically detect epileptic seizures that are transmitted to a mobile phone-based system for alerts and recording.

Study Overview

• Status: Terminated
• Conditions: Epilepsy, Tonic-Clonic
• Intervention / Treatment: Device: Embrace with Alert and Mate apps; Device: Embrace with Mate app only

• Study Type: Interventional
• Enrollment (Actual): 26
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Lausanne, Switzerland, 1011
    • Neurotech

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• male or female aged >18 years old
• clearcut diagnosis of epilepsy without evidence of non epileptic psychogenic seizure
• primary tonic clonic seizures or focal seizures evolving to generalized tonic clonic convulsion
• seizure frequency > 1 seizure/month during the last three months
• signed the informed consent form
• own a mobile phone device compatible with the embrace apps
• able to use the device without help from caregivers

Exclusion Criteria:

• patients aged less than 18 years old
• epilepsy diagnosis remains uncertain
• evidence of psychogenic non epileptic seizures
• seizure frequency below 1/month during any of the three previous months
• past-history of nickel allergy and contact dermatitis
• did not sign the informed consent form
• does not own mobile phone device compatible with the embrace apps
• cognitive or behavioral impairment preventing compliance or correct use of the device and app.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: SUPPORTIVE_CARE
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: experimental group; The experimental group will make use of the Alert app that sends alarms to patients mobile devices, and if desired to the mobile devices of their caregivers. This group will also use the Mate app which is used as a seizure diary	Device: Embrace with Alert and Mate apps; Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.; Other Names: experimental group's intervention
ACTIVE_COMPARATOR: Control group; The control group will only use the Mate app and not the Alert app. This group will thus not receive any notification, from the device, and will be unaware, of the devices performance	Device: Embrace with Mate app only; Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.; Other Names: Control group's intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The mean change from Baseline of the total score, of the french version of the Quality of life Epilepsy inventory-31	The change between the QOLIE-31 questionnaire total score measured at the first and the final visit will serve as primary endpoint. The possible range of each scale's final score is from 0 to 100. higher scores reflect better quality of life.	3 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The mean change from Baseline of the total scores of seven Quality of Life in Epilepsy Inventory-31 subscales covering the following epilepsy-specific domains:	Epilepsy-specific domains are: seizure worry, overall QOL, emotional well being, energy/fatigue subscales, medication effects, work-driving-social limits, cognitive function subscales. The possible range of each scale's final score is from 0 to 100. Higher scores reflect better quality of life.	3 month
Total number of true and false positives seizure detection	Detected by the embrace device, saved via the alert app and controlled by the patient via the mate app	3 month
The usability total score of Embrace and Mate apps	Will be assessed with the System usability scale (SUS). The score are to 0 from 100.	3 month
The utility total score of the system in general	will be assessed via a structured questionnaire-based interview that was Tailored for this study	3 month

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire Vaudois

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 10, 2018
• Primary Completion (ACTUAL): October 10, 2018
• Study Completion (ACTUAL): August 20, 2021

Study Registration Dates

• First Submitted: August 21, 2018
• First Submitted That Met QC Criteria: February 4, 2019
• First Posted (ACTUAL): February 6, 2019

Study Record Updates

• Last Update Posted (ACTUAL): July 22, 2022
• Last Update Submitted That Met QC Criteria: July 19, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: quality of life; epilepsy; mhealth
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epilepsy; Epilepsy, Generalized; Epilepsy, Tonic-Clonic
• Other Study ID Numbers: EMBQL

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No